PureTech's video game for AD­HD gets big Se­ries D fi­nanc­ing; Day One in­creas­es term sheet ahead of ex­pect­ed IPO

The mak­er of the first pre­scrip­tion video game treat­ment an­nounced it re­ceived $110 mil­lion in Se­ries D fi­nanc­ing Wednes­day.

Ak­ili’s En­deav­or­Rx is an FDA-ap­proved video game to im­prove at­ten­tion func­tion in chil­dren with AD­HD. The game is de­signed to tar­get at­ten­tion­al con­trol sys­tems in the brain and present sen­so­ry and mo­tor chal­lenges to ac­ti­vate the ner­vous sys­tems.

The com­pa­ny was found­ed by PureTech, the Boston-based bio­ther­a­peu­tics com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER